<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.32143.004</object-id><label>Table 1.</label><caption><title>Demographic, clinical and genetic features of the early detection cohort.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Gender</th><th>n</th><th>%</th><th>Ten-gene multiplex positive</th><th>TERT positive</th><th>Aneuploidy positive</th><th>UroSEEK positive</th><th>Cytology positive*</th><th>Uroseek or cytology positive*</th></tr></thead><tbody><tr><td colspan="9">Table 1a. Demographic, clinical and genetic features of the early&#160;detection cohort</td></tr><tr><td>Males without recurrence</td><td>172</td><td>59%</td><td>3 (2%)</td><td>10 (6%)</td><td>2 (1%)</td><td>13 (8%)</td><td valign="bottom">0 (0%)</td><td>13 (8%)</td></tr><tr><td>Males with recurrence</td><td>32</td><td>11%</td><td>26 (81%)</td><td>21 (66%)</td><td>19 (59%)</td><td>29 (91%)</td><td valign="bottom">16 (50%)</td><td>30 (94%)</td></tr><tr><td>Females without recurrence</td><td>81</td><td>28%</td><td>2 (2%)</td><td>2 (2%)</td><td>1 (1%)</td><td>5 (6%)</td><td valign="bottom">0 (0%)</td><td>5 (6%)</td></tr><tr><td>Females with recurrence</td><td>9</td><td>3%</td><td>4 (44%)</td><td>4 (44%)</td><td>3 (33%)</td><td>6 (67%)</td><td valign="bottom">1 (11%)</td><td>6 (67%)</td></tr><tr><td><italic>Indication</italic></td><td/><td/><td/><td/><td/><td/><td valign="bottom"/><td/></tr><tr><td>Hematuria without recurrence</td><td>346</td><td>61%</td><td>6 (2%)</td><td>15 (4%)</td><td>5 (1%)</td><td>22 (6%)</td><td valign="bottom">0 (0%)</td><td>17 (5%)</td></tr><tr><td>Hematuria with recurrence</td><td>163</td><td>29%</td><td>108 (66%)</td><td>90 (55%)</td><td>76 (47%)</td><td>134 (82%)</td><td valign="bottom">18 (11%)</td><td>32 (2%)</td></tr><tr><td>LUTS without recurrence</td><td>11</td><td>2%</td><td>0 (0%)</td><td>2 (18%)</td><td>0 (0%)</td><td>2 (18%)</td><td valign="bottom">0 (0%)</td><td>2 (18%)</td></tr><tr><td>LUTS with recurrence</td><td>3</td><td>1%</td><td>2 (67%)</td><td>1 (33%)</td><td>0 (0%)</td><td>2 (67%)</td><td valign="bottom">1 (33%)</td><td>2 (67%)</td></tr><tr><td>Other without recurrence</td><td>38</td><td>7%</td><td>1 (3%)</td><td>0 (0%)</td><td>1 (3%)</td><td>2 (5%)</td><td valign="bottom">0 (0%)</td><td>2 (5%)</td></tr><tr><td>Other with recurrence</td><td>9</td><td>2%</td><td>9 (100%)</td><td>8 (89%)</td><td>5 (56%)</td><td>9 (100%)</td><td valign="bottom">2 (22%)</td><td>9 (100%)</td></tr><tr><td><italic>Detected Tumor Diagnosis</italic></td><td valign="bottom"/><td valign="bottom"/><td/><td/><td/><td/><td valign="bottom"/><td valign="bottom"/></tr><tr><td>PUNLMP</td><td>2</td><td>1%</td><td>0 (0%)</td><td>1 (50%)</td><td>0 (0%)</td><td>1 (50%)</td><td valign="bottom">0 (0%)</td><td>0 (0%)</td></tr><tr><td>CIS</td><td>7</td><td>5%</td><td>4 (57%)</td><td>4 (57%)</td><td>1 (14%)</td><td>6 (86%)</td><td valign="bottom">3 (43%)</td><td>6 (86%)</td></tr><tr><td>LGTCC</td><td>31</td><td>21%</td><td>15 (48%)</td><td>18 (58%)</td><td>9 (29%)</td><td>22 (71%)</td><td valign="bottom">0 (0%)</td><td>4 (13%)</td></tr><tr><td>HGTCC</td><td>49</td><td>33%</td><td>34 (69%)</td><td>28 (57%)</td><td>26 (53%)</td><td>40 (82%)</td><td valign="bottom">4 (8%)</td><td>11 (22%)</td></tr><tr><td>INTCC</td><td>61</td><td>41%</td><td>48 (79%)</td><td>36 (59%)</td><td>35 (57%)</td><td>57 (93%)</td><td valign="bottom">9 (15%)</td><td>16 (26%)</td></tr><tr><td><italic>Cytology diagnosis*</italic></td><td/><td/><td/><td/><td/><td/><td valign="bottom"/><td valign="bottom"/></tr><tr><td>Positive</td><td>21</td><td>6%</td><td>16 (76%)</td><td>12 (57%)</td><td>16 (76%)</td><td>20 (95%)</td><td>N/A</td><td>N/A</td></tr><tr><td>Atypical</td><td>105</td><td>30%</td><td>21 (20%)</td><td>21 (30%)</td><td>12 (11%)</td><td>30 (29%)</td><td>N/A</td><td>N/A</td></tr><tr><td valign="top">Negative</td><td valign="top">221</td><td valign="top">64%</td><td valign="top">4 (2%)</td><td valign="top">9 (4%)</td><td valign="top">1 (0.4%)</td><td valign="top">12 (5%)</td><td valign="top">N/A</td><td valign="top">N/A</td></tr><tr><td colspan="9">Table 1b. Demographic, clinical and genetic features of the Surveillance cohort.</td></tr><tr><td><italic>Males without recurrence</italic></td><td>59</td><td>30%</td><td>3 (5%)</td><td>8 (14%)</td><td>3 (5%)</td><td>10 (17%)</td><td>0 (0%)</td><td>8 (14%)</td></tr><tr><td><italic>Males with recurrence</italic></td><td>90</td><td>45%</td><td>45 (50%)</td><td>53 (59%)</td><td>20 (22%)</td><td>59 (66%)</td><td>20 (22%)</td><td>53 (59%)</td></tr><tr><td><italic>Females without recurrence</italic></td><td>17</td><td>9%</td><td>5 (29%)</td><td>3 (18%)</td><td>0 (0%)</td><td>6 (35%)</td><td>0 (0%)</td><td>6 (35%)</td></tr><tr><td><italic>Females with recurrence</italic></td><td>33</td><td>17%</td><td>15 (45%)</td><td>19 (58%)</td><td>11 (33%)</td><td>33 (100%)</td><td>6 (18%)</td><td>19 (58%)</td></tr><tr><td><italic>Original Tumor Diagnosis</italic></td><td/><td/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td><italic>PUNLMP</italic></td><td>12</td><td>4%</td><td>5 (42%)</td><td>2 (17%)</td><td>1 (8%)</td><td>6 (50%)</td><td>0 (0%)</td><td>2 (17%)</td></tr><tr><td><italic>CIS</italic></td><td>25</td><td>8%</td><td>11 (44%)</td><td>13 (52%)</td><td>6 (24%)</td><td>14 (56%)</td><td>5 (20%)</td><td>10 (40%)</td></tr><tr><td><italic>LGTCC</italic></td><td>107</td><td>35%</td><td>27 (25%)</td><td>34 (32%)</td><td>8 (7%)</td><td>41 (38%)</td><td>0 (0%)</td><td>59 (55%)</td></tr><tr><td><italic>HGTCC</italic></td><td>62</td><td>20%</td><td>22 (36%)</td><td>24 (39%)</td><td>10 (16%)</td><td>30 (49%)</td><td>4 (7%)</td><td>16 (26%)</td></tr><tr><td><italic>INTCC</italic></td><td>104</td><td>34%</td><td>39 (38%)</td><td>47 (45%)</td><td>29 (28%)</td><td>54 (52%)</td><td>20 (19%)</td><td>34 (33%)</td></tr><tr><td><italic>Original Tumor Stage</italic></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td><italic>pTis</italic></td><td>25</td><td>8%</td><td>11 (44%)</td><td>13 (52%)</td><td>6 (24%)</td><td>14 (56%)</td><td>5 (20%)</td><td>10 (40%)</td></tr><tr><td><italic>pTa</italic></td><td>181</td><td>58%</td><td>54 (30%)</td><td>60 (33%)</td><td>19 (19%)</td><td>77 (43%)</td><td>4 (2%)</td><td>77 (43%)</td></tr><tr><td><italic>pT1</italic></td><td>71</td><td>23%</td><td>28 (39%)</td><td>35 (49%)</td><td>22 (31%)</td><td>39 (55%)</td><td>14 (20%)</td><td>23 (32%)</td></tr><tr><td><italic>pT2</italic></td><td>23</td><td>7%</td><td>9 (9%)</td><td>9 (39%)</td><td>7 (30%)</td><td>12 (52%)</td><td>5 (22%)</td><td>10 (43%)</td></tr><tr><td><italic>pT3</italic></td><td>9</td><td>3%</td><td>1 (11%)</td><td>2 (22%)</td><td>0</td><td>2 (22%)</td><td>1 (11%)</td><td>1 (11%)</td></tr><tr><td><italic>pT4</italic></td><td>1</td><td>0.3%</td><td>1 (100%)</td><td>1 (100%)</td><td>0</td><td>1 (100%)</td><td>N/A</td><td>N/A</td></tr><tr><td><italic>Routine cytology diagnosis*</italic></td><td/><td/><td/><td/><td/><td/><td valign="bottom"/><td valign="bottom"/></tr><tr><td><italic>Positive</italic></td><td>30</td><td>15%</td><td valign="bottom">21 (21%)</td><td>25 (83%)</td><td>20 (67%)</td><td>27 (90%)</td><td>N/A</td><td>N/A</td></tr><tr><td><italic>Atypical</italic></td><td>95</td><td>48%</td><td>38 (40%)</td><td>43 (45%)</td><td>18 (19%)</td><td>50 (53%)</td><td>N/A</td><td>N/A</td></tr><tr><td><italic>Negative</italic></td><td>71</td><td>36%</td><td>12 (17%)</td><td>13 (18%)</td><td>3 (4%)</td><td>19 (27%)</td><td>N/A</td><td>N/A</td></tr></tbody></table><table-wrap-foot><fn><p>*Cytology was available on only a subset of cases.</p><p>N/A Not Available.</p></fn></table-wrap-foot></table-wrap>